Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Iodixanol-320 Clear all
Completed Phase 4 Interventional Results available

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

NCT01848899
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Iodixanol, Ioxaglate, Bivalirudin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Results available

Isovue in Peripheral Digital Subtraction Angiography (DSA)

NCT01075217
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
iopamidol, iodixanol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 20, 2026, 4:10 PM EDT
Completed No phase listed Observational

Follow-up Study to Previous CARE Trial

NCT00479024
View directory record Official record
Conditions
Moderate to Severe Chronic Kidney Disease
Interventions
iodinated contrast agent
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Contrast Agents During CT Angiography

NCT01534975
View directory record Official record
Conditions
Contrast Enhancement on Cardiac CT
Interventions
contrast agent
Diagnostic Test
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Moderate Fall in eGFR

NCT01136876
View directory record Official record
Conditions
Coronary Artery Stenosis
Interventions
Iopamidol, Iodixanol-320
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Springfield, Illinois • New Brunswick, New Jersey • Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 20, 2026, 4:10 PM EDT
Completed No phase listed Observational Results available

Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care

NCT00783302
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 20, 2026, 4:10 PM EDT
Terminated Not applicable Interventional

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

NCT01188486
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC), Mesothelioma
Interventions
Stereotactic Body Radiation Therapy (SBRT), Computed Tomography (CT), Cyberknife, Trilogy, True Beam, Iohexol, Iodixanol
Radiation · Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 3 Interventional Results available

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
Drug · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 20, 2026, 4:10 PM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00348608
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 4 Interventional

Detection of Pulmonary Embolism With CECT

NCT00351754
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Isovue
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 20, 2026, 4:10 PM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00335335
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 4 Interventional

A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography

NCT00289029
View directory record Official record
Conditions
CIN
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Normal eGFR

NCT01137786
View directory record Official record
Conditions
Coronary Artery Stenosis
Interventions
Non ionic contrast media comparator
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 20, 2026, 4:10 PM EDT
Withdrawn Not applicable Interventional

Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli

NCT01935141
View directory record Official record
Conditions
Multiple Pulmonary Emboli
Interventions
Low-Dose IV Contrast, Siemens Sensation 64-MDCT scanner., Visipaque 320 non-ionic isoosmolar contrast agent
Procedure · Device · Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 20, 2026, 4:10 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

NCT00793182
View directory record Official record
Conditions
Renal Impairment
Interventions
Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 20, 2026, 4:10 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

NCT02063594
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NCTX (PEGylated Liposomal Iodixanol Injection), Saline Placebo
Drug
Lead sponsor
Marval Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 4 Interventional

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

NCT05065073
View directory record Official record
Conditions
Coronary Artery Disease, Contrast Media Reaction
Interventions
Iodixanol, Iohexol
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Not applicable Interventional

Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan

NCT01843426
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Not applicable Interventional

A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain

NCT00348569
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
64 Channel VCT
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 20, 2026, 4:10 PM EDT
Terminated No phase listed Observational

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

NCT01326364
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic body radiotherapy, Iodixanol, Iohexol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 20, 2026, 4:10 PM EDT
Withdrawn Phase 1 Interventional

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

NCT05490381
View directory record Official record
Conditions
Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
Interventions
Iodixanol, Angiogram, Arterial Embolization, Polyvinyl Alcohol, Ethiodized Oil, Computed Tomography, Chart Abstraction
Other · Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 20, 2026, 4:10 PM EDT
Terminated Phase 4 Interventional Results available

Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients

NCT00782639
View directory record Official record
Conditions
Chronic Renal Impairment, Diabetes Mellitus
Interventions
Iopamidol injection 76%, iodixanol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 20, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Results available

Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis

NCT01376089
View directory record Official record
Conditions
Patient Comfort and Safety
Interventions
Iodixanol, Iopamidol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 20, 2026, 4:10 PM EDT